June 26, 2024- Vizient, Inc. examines pulsed field ablation technologies for atrial fibrillation and the role wearable monitoring devices can play in women’s cardiovascular health in the latest Medical Device Tech Watch. “New technologies—like pulsed field ablation and wearable heart monitoring—and clinical decision support tools present providers with the opportunity to improve care pathways and determine how to provide cost-effective care,” said Bonnie Lai, senior vice president and general manager, Vizient. “By working closely with providers, we have developed best practices for operationalizing the use of these innovative technologies and tools.”
Featured articles include:
(1) Top three questions providers are asking about the latest in electrophysiology technology: pulsed field ablation — As atrial fibrillation becomes more common and poses a greater burden on patients and healthcare systems, a need has arisen for efficient and coordinated cardiovascular care. The promising clinical results from pulsed field ablation (PFA) have generated a wave of enthusiasm and interest with a major study reporting a 60-70% success rate for patients living a-fib free after one year. Supply utilization and reimbursement policies will determine the margin impact of PFA. But with a lower risk of injury than other a-fib ablation modalities, most hospitals with comprehensive electrophysiology programs are exploring this new technology.